(Q35076925)

English

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

phase II clinical trial

0 references

author name string

Masanori Noguchi

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Fukuko Moriya

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Shigetaka Suekane

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Rei Ohnishi

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Satoko Matsueda

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Tetsuro Sasada

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Akira Yamada

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kyogo Itoh

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

30 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

613

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Improved Endpoints for Cancer Immunotherapy Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

8 July 2018

Personalized peptide vaccination in patients with refractory non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

27 September 2018

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

27 September 2018

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

27 September 2018

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

27 September 2018

Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

27 September 2018

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3882108

27 September 2018

Platelet serotonin 5-HT2A receptor binding in patients with carcinoid tumor

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-613

21 January 2018

New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low‐dose estramustine in HLA‐A24‐positive patients with castration‐resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24373380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-13-613

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35076925&oldid=2197220466"